Table 1.

Baseline characteristics of women with osteoporosis treated with alendronate alone (group 1), teriparatide alone (group 2), or both (group 3)

Characteristic (normal range)	Group 1 Alendronate (n = 29)	Group 2 Teriparatide (n = 20)	Group 3 Both (n = 20)	P value
Age (yr)	64 ± 6	65 ± 7	62 ± 7	0.28
Height (cm)	162 ± 6	163	161 ± 5	0.36
Weight (kg)	67 ± 11	67 ± 11	66 ± 12	0.92
Body mass index	25.6 ± 4.5	24.9 ± 3.6	25.4 ± 5.1	0.87
Calcium intake (mg/d)	1234 ± 530	1269 ± 724	1180 ± 585	0.91
25-Hydroxyvitamin D (ng/ml) (>15)a	30 ± 16	27 ± 12	27 ± 11	0.64
PTH (pg/ml) (10–60)	33 ± 14	32 ± 12	35 ± 8	0.80
Serum creatinine (mg/dl) (0.6–1.5)	0.8 ± 0.1	0.8 ± 0.1	0.8 ± 0.2	0.99
Estimated GFR (ml/min)b (≥60)	77 ± 24	76 ± 24	77 ± 28	0.99
OC (ng/ml) (not available)	28.4 ± 10.8	28.1 ± 10.4	29.7 ± 8.2	0.87
P1NP (ng/ml) (2.1–86.1)	48.7 ± 16.9	49.6 ± 13.6	48.2 ± 15.8	0.46
N-telopeptide (nm BCE) (8.0–27.6)	14.8 ± 4.0	15.7 ± 4.2	16.3 ± 7.3	0.60
BMD (g/cm2)
Posterior-anterior spine	0.808 ± 0.120	0.815 ± 0.106	0.810 ± 0.143	0.98
T score	−2.2 ± 1.1	−2.1 ± 1.0	−2.2 ± 1.4
Femoral neck	0.646 ± 0.092	0.605 ± 0.073	0.660 ± 0.085	0.10
T score	−1.9 ± 0.8	−2.2 ± 0.7	−1.7 ± 0.8
Total hip	0.768 ± 0.109	0.746 ± 0.100	0.802 ± 0.097	0.22
T score	−1.5 ± 0.9	−1.6 ± 0.8	−1.2 ± 0.8
One third radius	0.597 ± 0.093	0.584 ± 0.085	0.617 ± 0.091	0.51
T score	−1.7 ± 1.6	−1.9 ± 1.5	−1.3 ± 1.5
Total body	0.839 ± 0.087	0.833 ± 0.080	0.849 ± 0.085	0.84
T score	NA	NA	NA
Quantitative computed tomography bone density (g/cm3)	87 ± 21	85 ± 23	96 ± 23	0.26
T score	−3.1 ± 0.7	−3.1 ± 0.8	−2.8 ± 0.9

Data shown are for all subjects in the per-protocol analyses. Values are the mean ± sd. The last column shows the P values determined by analysis of variance for all three groups. BCE, Bone collagen equivalents. 

^aTo convert to nanomoles per liter, multiply by 2.496. The normal range for 25-hydroxyvitamin D is given at the time the subjects were enrolled. 

^bGlomerular filtration rate (GFR) estimated using the Cockcroft Gault equation.